EVE Investments Ltd (ASX:EVE) is witnessing traction for a medical technology company that it has a 38% interest in named Omni Innovation.
Omni Innovation has a licence agreement with Eagle Health for the manufacture and distribution of Hutang-1, a pre-meal drink for people with type II diabetes and pre-diabetes.
During the March quarter, Hutang-1 increased its reach to over 80,000 consumers, including over 24,000 diabetes or pre-diabetes patients and showed promising conversion to sales.
Four stores in China
This commercial roll-out is being conducted with four dedicated retail stores in Xiamen, China and a direct community outreach program.
Eagle Health are scaling up more specialty stores beyond Xiamen and into other Chinese regions in the current June quarter and expect the trend in traffic and sales conversion to further increase.
A company focused on medical technology investment
EVE is an ASX listed investment company focused on investing in medical technology companies.
It has a preference for Australian based companies that have global scale and to date has two investment partners, Meluka Honey and Omni Innovation.